

Mission

Provide an FDA-compliant capability to protect life and prevent disease through treatment with novel investigational countermeasures against man-made or natural threats in accordance with federal regulations and DoD Instructions.

For more information about USAMMDA

Visit our website:

www.usammda.army.mil

Or contact us at:

FHP-IND

1430 Veterans Drive, Fort Detrick, MD 21702

301-619-1104

USAMMDA

U.S. Army Medical Materiel Development Activity



*Developing Quality Medical Products
for U.S. Forces*

How we can help:

- Assist in securing product
- Assist primary investigator support staff in fulfillment of regulatory requirements
- Provide subject matter expertise

Force Health Protection- Investigational New Drugs



Capabilities

- Executing FHP-IND protocols in accordance with federal regulations and DoD Instructions
- Acquisition, storage, and testing of FHP-IND products
- Deployable team of health professionals capable of executing the FHP-IND mission
- Investigational countermeasure identification



For additional information, contact:

FHP-IND Division Director

DSN: 343

Office: 301-619-6824

USAMMDA.Force.Health.Protection@amedd.army.mil



U.S. Army Medical Research and Materiel Command

Protect the Warrior, Sustain the Force

Safe & Compliant

Updated: December 12, 2011

Force Health Protection- Investigational New Drugs

Force Health Protection-Investigational New Drugs (FHP-IND) serves under the auspices of the Office of the Surgeon General (OTSG) Executive Agency Directorate. FHP-IND is the lead component for managing of DoD directed Investigational New Drug (IND) protocols and the Specialized MEDCOM Response Capabilities – Investigational New Drug (SMRC-IND) team.



FHP-IND currently has four product managers overseeing IND products and associated protocols. Product managers coordinate administrative, clinical, and regulatory activities needed to maintain and successfully activate the protocols worldwide. The Deputy Director oversees sustainment and training of the SMRC-IND teams, deployable assets for MEDCOM to conduct on-site support for Chemical, Biological, Radiological, and Nuclear (CBRN) incidents when IND products are indicated.

FHP-IND is organized into three components:

1. Portfolio Development

Provides logistical, regulatory, and operational support for force health protection contingency and treatment IND protocols.

2. Countermeasure Surveillance

Identifies, evaluates, and recommends investigational medical countermeasures with the potential to counter CBRN threats and emerging diseases.




3. SMRC - IND Team(s)

Deploy(s) in support of military and civilian authorities to provide the capability to use novel investigational countermeasures in response to domestic and international disasters or CBRN attacks in accordance with federal regulations and DoD instructions. There are two seven person teams.

Team Composition:

1. Team Leader
2. Infectious Disease Physician
3. Clinical Research Coordinator/Nurse
4. Healthcare Specialist/Medic
5. Medical Supply Specialist
6. Information Management Specialist
7. Product Manager

Global Capabilities with Pre-positioned Products



Treatment Capabilities

- Smallpox
- Vaccinia adverse reaction
- Botulism
- Anthrax post-exposure
- Hemorrhagic Fever with Renal Syndrome
- Crimean Congo Hemorrhagic Fever (CCHF) and Lassa Fever
- Leishmaniasis
- Snake and scorpion bites

